Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% versus chemotherapy.